SCHEMBL4635913

SCHEMBL4635913

CCOC(=O)c1ccc(N2CC3C(N)C3C2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 5/20 0.54
HPGD P15428 2/20 0.54
LMNA P02545 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
MAOA P21397 1/20 0.51
ALDH1A1 P00352 6/20 0.51
HSP90AA1 P07900 1/20 0.51
CACNA1B Q00975 1/20 0.51
APBA1 Q02410 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
MAPK1 P28482 1/20 0.50
DPP4 P27487 1/20 0.49
PREP P48147 1/20 0.49
DPP8 Q6V1X1 1/20 0.49
DPP9 Q86TI2 1/20 0.49
DPP7 Q9UHL4 1/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2690900 0.84 ATM (0.53) LMNAALDH1A1MAPK1SMN1; SMN2
SCHEMBL2690898 0.84 ATM (0.53) LMNAALDH1A1MAPK1SMN1; SMN2
SCHEMBL2690896 0.84 ATM (0.53) LMNAALDH1A1MAPK1SMN1; SMN2
SCHEMBL14331881 0.84 HTT (0.58) HTTHPGDLMNACYP1A2CYP3A4
SCHEMBL847669 0.82 HTT (0.56) HTTHPGDLMNACYP1A2CYP3A4
SCHEMBL383362 0.81 PRKD3 (0.56) HTTHPGDLMNACYP1A2CYP3A4
SCHEMBL382516 0.81 PRKD3 (0.56) HTTHPGDLMNACYP1A2CYP3A4
SCHEMBL63005 0.80 HTT (0.54) HTTHPGDLMNACYP1A2CYP3A4
SCHEMBL6132378 0.80 ALDH1A1 (0.62) HTTHPGDLMNACYP1A2CYP3A4
SCHEMBL6132380 0.80 ALDH1A1 (0.62) HTTHPGDLMNACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080300251-A1 Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors RANBAXY LABORATORIES LIMITED (IN) 2008-12-04 US disclosed
EP-1931633-A2 DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS Ranbaxy Laboratories Limited (IN) 2008-06-18 EP disclosed
WO-2007029086-A2 DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300251-A1 Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors DPP4, DPP3, DPP8 HTT 2870/4885HPGD 2646/4885LMNA 3634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.